ema tirzepatide Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 26-29 January 2026 2025 New Drug Approvals: Key

The craving got quieter, and they were able to move on

Among the resulting 500,000 patients, it was found that after 12 months of GLP-1 use, there was a significantly elevated risk of users developing androgenic alopecia, telogen effluvium, and non-scarring hair loss

GLP-1 shots versus pills, convenience or more weight loss Injectable GLP-1s have shown slightly higher effectiveness for weight loss in clinical trials compared to oral versions

25 In CY-5 experiments, Asp 21 from GIP was replaced by Ala

When properly vetted, these providers can serve as trustworthy sources for safe and effective GLP-1 treatment at a more accessible price